Status and phase
Conditions
Treatments
About
This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up period.
The study is designed to enroll 20-31 subjects, with 14-20 subjects expected to be evaluable, in an "autologous tumor-infiltrating lymphocyte therapy" regimen that includes:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
31 participants in 1 patient group
Loading...
Central trial contact
Haifeng Qin, PhD; Yongsheng Wang, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal